Thomas Reiser: Final Day as Executive Director – Closing a Remarkable Chapter at ISTH
Thomas Reiser, Executive Director at the International Society on Thrombosis and Haemostasis, shared a post on LinkedIn:
“Today is my final day as Executive Director at the International Society on Thrombosis and Haemostasis (ISTH).
I close this remarkable 14+ year chapter with immense gratitude for the trust placed in me, for the privilege of serving a mission and organization I believe so deeply in, and for the many extraordinary people who made this journey meaningful every step of the way.
To the ISTH team, Council, volunteers, members, partners, and the hashtag#thrombosis and hashtag#hemostasis community around the world: Thank you for allowing me to be part of this amazing community, the collaboration, dedication, and the friendships that will stay with me long after today.
I leave with great pride for all we have been able to accomplish together.
At the same time, I look forward to continuing to create impact, wherever the next chapter may lead me.
With heartfelt thanks and deep appreciation.”

Find more posts featuring Thomas Reiser on Hemostasis Today.
-
Feb 26, 2026, 15:58Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
-
Feb 26, 2026, 15:51Augustina Isioma Ikusemoro: The Real Miracle in Trauma Care Happens Behind the Scenes
-
Feb 26, 2026, 15:42Jim Hoffman։ Targeting NETosis to Improve Perfusion and Reduce Thrombosis in AMI
-
Feb 26, 2026, 15:40Elvira Grandone: ISTH Launches An International Survey to Capture Real-World Practice of Pregnancy Anemia
-
Feb 26, 2026, 15:39Ashok Yadav: Placental Glycogen as a Vital Energy Reserve for Fetal and Placental Health
-
Feb 26, 2026, 15:37Nayab Ahmed: Main Reasons for Washing Platelet-Rich Plasma
-
Feb 26, 2026, 15:36Robert Negrin Shares His Outlook for the Year Ahead as ASH President
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke